{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003382","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.075265+00:00","generated_at":"2026-06-26T23:52:46.270229+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023","bullets":["Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).","Cash and securities $194.8M at Jan 31, 2022, down from $248.9M at Apr 30, 2021.","Initiated Phase 3 KONFIDENT trial for KVD900 on-demand HAE treatment; data expected H2 2023.","Phase 2 KOMPLETE trial for KVD824 (prophylaxis) enrolling on track; data expected mid-2023.","Factor XIIa inhibitor program advancing; first IND anticipated in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003382","json":"https://secwatch.observer/filing/0000950170-22-003382.json","markdown":"https://secwatch.observer/filing/0000950170-22-003382.md","text":"https://secwatch.observer/filing/0000950170-22-003382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/0000950170-22-003382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/kalv-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:52:46.270229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}